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Abstract
Retinoblastoma is the most common intraocular tumor in children. Malfunctioning of many signaling pathways regulating
cell survival or apoptosis, make the disease more vulnerable. Notably, resistance to chemotherapy mediated by MRP-1, lung-
resistance protein (LRP) is the most challenging aspect to treat this disease. Presently, much attention has been given to the
recently developed anticancer drug nutlin-3a because of its non-genotoxic nature and potency to activate tumor
suppressor protein p53. However, being a substrate of multidrug resistance protein MRP1 and Pgp its application has
become limited. Currently, research has step towards reversing Multi drug resistance (MDR) by using curcumin, however its
clinical relevance is restricted by plasma instability and poor bioavailability. In the present investigation we tried to
encapsulate nutlin-3a and curcumin in PLGA nanoparticle (NPs) surface functionalized with folate to enhance therapeutic
potential of nutlin-3a by modulating MDR. We document that curcumin can inhibit the expression of MRP-1 and LRP gene/
protein in a concentration dependent manner in Y79 cells. In vitro cellular cytotoxicity, cell cycle analysis and apoptosis
studies were done to compare the effectiveness of native drugs (single or combined) and single or dual drug loaded
nanoparticles (unconjugated/folate conjugated). The result demonstrated an augmented therapeutic efficacy of targeted
dual drug loaded NPs (Fol-Nut-Cur-NPs) over other formulation. Enhanced expression or down regulation of proapoptotic/
antiapoptotic proteins respectively and down-regulation of bcl2 and NFkB gene/protein by Fol-Nut-Cur-NPs substantiate
the above findings. This is the first investigation exploring the role of curcumin as MDR modulator to enhance the
therapeutic potentiality of nutlin-3a, which may opens new direction for targeting cancer with multidrug resistance
phenotype.
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Introduction
Retinoblastoma is the third most common form of cancer in
infants and is an ocular disease that requires attention, as in
approximately 90% of cases metastatic retinoblastoma is lethal [1].
Chemotherapy is the treatment of choice following enucleation in
patients with nerve and choroid invasion and orbital extension [2].
However, their clinical use is limited by systemic toxicity, rapid
blood clearance and nonspecific side effects. Further, multidrug
resistance also plays a vital role in limiting the therapeutic
potential of many anti-neoplastic agents in retinoblastoma. For the
majority of anticancer drugs, apoptosis appears to be initiated by
intrinsic or extrinsic pathways. Interestingly, an altered apoptosis
regulatory pathway plays an imperative function in exhibiting
chemo-resistance in retinoblastoma. Over expression of antiapop-
totic protein bcl2 has been observed in retinoblastoma leading to
decreased chemo-sensitivity [3]. Interestingly, retinoblastoma is
caused by mutation in both alleles of the retinoblastoma gene
RB1. Although, the tumor suppressor protein p53 remains
functional but its activity is highly regulated by its negative
regulator murin double minute (MDM2) [4]. Above all these
resistance mechanisms, classical multidrug resistance (MDR)
mediated via trans-membrane transporters like MRP-1 and LRP
contribute to foremost resistance mechanism against various
anticancer drugs in retinoblastoma. Multidrug resistance protein
(MRP-1) encoded by MRP-1 gene belongs to the family of ABC
membrane transporters (ABCC1) and in a similar manner as P-gp,
mediates resistance to a range of structurally and functionally
unrelated agents [5]. Similarly, LRP has been identified as major
vault protein in human and is over expressed in 58% of
retinoblastoma tumors [2]. The protein is encoded by LRP gene
and mechanism of action of this protein in eliciting MDR is yet to
be explored. It has been investigated intensively that, these two
proteins (MRP-1 and LRP) are solely associated with multidrug
resistance in retinoblastoma [6,7]. Thus, considering the relative
importance of MDR in retinoblastoma, there is an urgent call for
effective therapeutic strategy in retinoblastoma therapy.
Recently the anticancer drug nutlin-3a has shown its therapeu-
tic efficacy in diverse cancer like osteosarcoma, leukemia, colon
cancer etc. [8,9] and much attention has been given for its use in
retinoblastoma therapy, because of its nongenotoxic nature [4].
Nutlin-3a is an antagonist of murin double minute (MDM2) and
actively inhibits p53-MDM2 interaction. Binding to the same site
on MDM2 as p53, nutlin-3a effectively inhibit MDM2-mediated
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between p53-MDM2 and results in p53 accumulation and
activation [9]. In the present scenario though nutlin-3a is a potent
candidate for cancer therapy, however its clinical application is
limited by the fact that it acts as a substrate for multidrug
resistance proteins MRP-1 and Pgp [10]. Hence, novel strategy is
warranted to enhance the antiproliferative and apoptotic activity
of nutlin-3a by modulating multidrug resistance. The polyphenolic
compound curcumin extracted from the rhizome of turmeric
(Curcuma longa) has been investigated intensively for its application
as MDR modulator. Many research groups have shown that
cucumin can effectively modulate the expression and function of
major MDR proteins (Pgp, MRP, LRP, and BCRP) in diverse
cancer cell lines [11–13]. Recently, Thiyagarajan et al. have
explored that; curcumin can down regulate the expression of LRP
protein and mRNA in a concentration dependent manner in Y79
retinoblastoma cell line [7]. Additionally, curcumin has potent
anticancer properties as demonstrated in a plethora of human
cancer cell line and animal carcinogenesis model [14]. Inhibition
of the NFkB signaling pathway, activation of p53 pathway,
suppression of bcl-2 proteins is also considered to be important for
the pro-apoptotic activity of curcumin [14–16]. Although,
curcumin is a potential modulator of MDR proteins and can
target many signaling pathways, but its optimum potential is
limited by poor aqueous solubility, short plasma half-life, poor
bioavailability and non-specific delivery [17]. Presently, many
group worked to enhance the solubility and pharmacokinetic
property of native curcumin by encapsulating it in polymeric
nanocarrier systems [18]. In this milieu, Mohanty et al. have
demonstrated that encapsulation of curcumin in glycerol mono-
oleate based nanoparticle (GMO NP) enhances its bioavailability
and therapeutic activity to many folds compared to native
curcumin [19]. Thus, by encapsulating curcumin in polymeric
nanoparticles one can efficiently use it for anticancer therapy and/
or modulating drug resistance.
Drug combinations have played a particularly prominent role in
the treatment of cancer [15,20]. Administration of a combination
of agents hitting different targets and displaying different toxicity
profiles can improve the therapeutic index either in the form of
better efficacy and reduced toxicity. To reverse the resistance
mechanisms and reduce side effects during chemotherapy, a
promising approach is to combine a conventional chemotherapy
with new strategies such as chemosensitizers with cytotoxic activity
to inhibit ABC transporters and display antiproliferative activity
[15,21]. Recently, Patil et al. have shown that simultaneous
delivery of tariquidar with paclitaxel in PLGA NPs overcomes
multidrug resistance and enhances therapeutic effect of paclitaxel
in drug resistance breast cancer cells [21]. Hence, we can
anticipate that co-delivery of curcumin with nutlin-3a may emerge
as a new strategy to overcome resistance of nutlin-3a in drug
resistance cancer cells.
With this background, we hypothesize that, by encapsulating
anti-cancer drug nutlin-3a and chemosensitizer curcumin in
polymeric nanoparticles prepared from biocompatible and
biodegradable polymers like PLGA, we can overcome the
shortcomings associated with conventional drug delivery strategy.
Further, by modulating MDR function through curcumin we can
enhance the anticancer activity of nutlin-3a in drug resistance Y79
cells. Additionally, to increase the therapeutic efficacy of our dual
drug loaded NPs; a targeted tumor-specific strategy is warranted.
In this regard, folate receptor (FR) stands out as one of the most
promising and extensively investigated epithelial cancer markers
for drug targeting [19,22]. Thus, solid tumors like retinoblastoma
that are currently most difficult to treat by classical therapeutic
modalities may be readily targeted with folate-linked therapeutics
or carrier systems [23]. In the present study we have surface
functionalized our dual drug loaded PLGA NPs with folate to
interfere MDR of Y79 retinoblastoma cell. As our aim was to
overcome drug resistance of Y79 cell by nutlin-3a-curcumin co-
loaded NPs, we first investigated the effect of curcumin to down
regulate expression of MDR proteins MRP-1 and LRP. Further,
we investigated several biological parameters by cellular assays
(measurement of cytotoxicity, loss of mitochondrial membrane
potential, apoptosis) and found that dual drug loaded NPs
contribute to a synergistic activation of antiproliferative and
antiapoptotic activity in multidrug resistance Y79 cells. Hence our
results demonstrated that, co-administration of nutlin-3a with an
MDR modulator like curcumin, in polymeric NPs surface
functionalized with folate would be significantly beneficial by
augmenting the therapeutic effects and improving clinical
outcomes, in cancer with multidrug resistance phenotype.
Materials and Methods
Reagents and cell lines
Nutlin-3a was purchased from Cayman Chemical Company
(Michigan, U. S. A.) Poly (D, L-lactide-co-glycolide) PLGA,
copolymer ratio 50:50, inherent viscosity (I.V=0.41) was
purchased from Birmingham polymers, Inc. (Birmingham, AL,
U. S. A.). N-hydroxysulfosuccinamide (Sulfo-NHS), 1, 3, Dicyclo-
hexyl carbodiimide (DCC), polyvinyl alcohol (PVA, average MW
30,000–70,000), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazo-
lium bromide (MTT), Annexin-V-FITC, protease inhibitor
cocktail, propidium iodide, 5,59,6,69-tetrachloro-1,19,3,39-tetra-
ethylbenzimidazolocarbocyanine iodide (JC-1) and sodium dode-
cyl sulfate, folic acid, curcumin were purchased from Sigma-
Aldrich Co. (St Louis, MO, U. S. A.). 1-ethyl-3-(3-dimethylami-
nopropyl) carbodiimide hydrochloride (EDC), potassium dihydro-
gen phosphate and Tris base were obtained from Qualigens,
Mumbai, INDIA. All primary antibodies, horseradish peroxidase-
conjugated secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, U. S. A).Y79, A549, HEK293 and
SIHAcellswerepurchasedfromAmericanTypeCultureCollection
(ATCC,Manassas,VA)and weregrowninRPMI 1640 (Invitrogen,
CA, U. S. A.) media supplemented with 10% fetal bovine serum,
100 mg/ml penicillin G and 100 mg/ml streptomycin (Invitrogen,
USA) at 37uC in a humidified atmosphere containing 5% CO2
(Hera Cell, Thermo Scientific, Waltham, MA).
Preparation of drug loaded PLGA nanoparticles
Drug loaded PLGA NPs were formulated by oil-in-water single
emulsion-solvent evaporation technique [24]. In brief, a solution of
100 mg PLGA polymer and 10 mg drug (nutlin-3a or curcumin)
corresponding to 10% w/w dry weight of polymer in 3 ml of
chloroform was emulsified in 12 ml of 2% w/v aqueous solution of
PVA to form an oil-in-water emulsion. In case of dual drug loaded
nanoparticles, both the drugs were added in 1:1 ratio such that the
total drug in the formulation corresponded to 10% w/w dry
weight of polymer. The emulsification was carried out using a
micro-tip probe sonicator set at 55 W of energy output (VC 505,
Vibracell Sonics, Newton, USA) for 2 min over an ice bath. The
emulsion was stirred overnight at room temperature to allow
evaporation of organic solvent and formation of NPs. NPs were
recovered by ultracentrifugation at 1,00,000 g for 20 min at 4uC
(Sorvall Ultraspeed Centrifuge, Kendro, USA), washed twice with
water to remove excess PVA and unencapsulated drug. The
nanoparticulate suspension was then lyophilized for 2 days
(247uC and ,10 mm mercury pressure, LYPHLOCK 12,
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further use.
Surface functionalization of drug loaded NPs with folate
ligand
In brief, folic acid was reacted with DCC and NHS in DMSO
at stoichiometric molar ratio of Fol/DCC/NHS=1/1.2/2 for
6 hrs at 50
uC [25]. The product was filtered to remove N, N-
dicyclohexylurea (DCU). The activated folate was then reacted
over night with ethylene diamine in presence of pyridine as
catalyst. The aminated folate (Fol-NH2) was precipited out by
adding excess cold acetonitrile, followed by vacuum filtration. For
conjugation of Fol-NH2 onto the surface of PLGA NPs, 10 mg of
drug loaded NPs (nutlin-3a loaded NPs (Nut-NPs), curcumin
loaded NPs (Cur-NPs), nutlin-3a and curcumin loaded NPs (Nut-
Cur-NPs)) were dispersed in 5 ml of PBS (0.02 M, pH 7.4)
followed by addition of 250 ml of EDC (1 mg/ml) and 250 mlo f
NHS (1 mg/ml) to the above suspension. EDC activation was
carried out by agitating the above suspension for 2 hrs at room
temperature using a magnetic stirrer. Excess of unreacted EDC
and NHS were removed and activated NPs were recovered by
ultracentrifugation at 1, 00, 000 g for 20 min at 4uC (Sorvall
Ultraspeed Centrifuge, Kendro, USA). The activated NPs were
dispersed in 2 ml of PBS (0.02 M, pH 7.4) followed by addition of
100 ml of aminated folate solution (1mg/ml in PBS). The solution
was again agitated for 2 hrs at room temperature and excess of
unconjugated folate was removed by ultracentrifugation. The
recovered folate conjugated NP suspension was lyophilized for
further use [26]. Conjugation of folate onto PLGA NPs surface
was confirmed by FTIR analysis (Methods S1).
Characterization of drug loaded PLGA NPs
Particle size analysis and zeta potential measure-
ment. Particle size and size distribution (polydispersity index)
of the formulations were determined, by dynamic light scattering
(DLS), using a Zetasizer (Nano ZS, ZEN3600, Malvern
Instrument, UK) with a wavelength of 532 nm at 25
oC with an
angle detection of 90
o [27]. In brief, , 1 mg/ml of nano-
particulate suspension were prepared in MilliQ water, sonicated
for 30 sec over an ice bath using a sonicator (VC 505, Vibracell
Sonics, Newton, USA) set at 55 W of energy output. A 100 mlo f
the above NPs suspension was diluted to 1 ml in water and then
subjected to particle size measurement. Zeta potential of the
nanoformulations was determined by the same instrument,
following the above protocol. All measurements were performed
in triplicates.
Transmission electron microscopy (TEM). Nanoparticles
were also evaluated for size by transmission electron microscope
(Philips/FEI Inc. Barcliff, Manor, NY). For this purpose, a sample
of NPs (0.5 mg/ml) was suspended in water and sonicated for
30 sec. One drop of this suspension was placed over a carbon
coated copper TEM grid (150 mesh, Ted PELLA Inc. Rodding,
CA) and negatively stained with 1% uranyl acetate for 10 min,
allowed to dry and the images were visualized at 120 kV under
microscope.
Evaluation of encapsulation efficiency of nutlin-3a and
curcumin. Encapsulation efficiency was determined by the
reverse phase isocratic mode of high performance liquid
chromatography (RP-HPLC) method, using Agilent 1100 HPLC
(Agilent technologies, Waldbronn Analytical Division, Germany)
which consists of Zorbax Eclipse XDB-C18, 15064.6 mm, i.d with
internal standard of dimethylphthalate. To estimate entrapped
drugs in NPs, 5 mg of freeze dried drug loaded NPs (containing
single drug or dual drug) was dissolved in 5 ml of acetonitrile and
kept in the shaker at 37uC and 2 g (Wadegati Labequip, India) for
2 days. The samples were then centrifuged at 17,458 g for 10 min
at 25uC (SIGMA 3K30, Munich, Germany) to extract the drug
present in the solution. The collected supernatant was analyzed for
drug content by RP-HPLC using specific mobile phase for each
drugs, at a flow rate of 1 ml/min, at 30uC with thermostat (Model
No -G1316A) [28,29]. The percentage encapsulation efficiency of
each drug was calculated by dividing the amount of drug
entrapped by the total amount of drug used in formulation,
multiplied by 100.
In vitro release kinetics of different encapsulated drugs
from NPs. The release kinetics of drugs from NPs was carried
out in an in vitro condition [30]. In brief, 10 mg of drug loaded
unconjugated and folate conjugated NPs was dispersed in 3 ml of
PBS (0.01 M, pH 7.4) containing 0.1% v/v of Tween 80 (which
was added to maintain a sink condition for hydrophobic drug).
The nanoparticulate suspension was equally divided in three tubes
1 ml each (as experiment was performed in triplicates) and kept in
a shaker at 37uC at 2 g (Wadegati Labequip, India). At particular
time intervals samples were taken out from shaker and centrifuged
at 17,458 g, 25uC (SIGMA 3K30, Munich Germany) for 10 min.
The collected supernatants were lyophilized for 2 days. To the
pellet obtained after centrifugation, 1 ml of fresh PBS-Tween 80
solution was added and placed in shaker for next readings. The
lyophilized sample was dissolved in 1 ml of acetonitrile and kept in
the shaker at 37uC and 2 g (Wadegati Labequip, India) for 2 days.
After 2 days, the sample was centrifuged at 17,458 g for 10 min at
25uC to collect the drug in supernatant. 20 ml of this supernatant
was injected in the HPLC to determine the amount of drug
released with respect to different time intervals.
Expression study of MDR mRNA and proteins
To detect expression of major MDR genes, Y79, A549 (MRP-1
and LRP positive), SIHA (LRP negative) and HEK (MRP-1
negative) cell lines (at a density of 50610
5 cells) were taken and
total endogenous mRNA from all above mentioned cells was
isolated using the RNeasy Mini kit (Qiagen, Hamburg, Germany)
according to the manufacturer’s instructions. RNA was treated
with DNAse (Qiagen, Hamburg, Germany) to eliminate any DNA
contamination. Total RNA (l mg) was reverse-transcribed to cDNA
using M-MLV reverse transcriptase and oligo (dT) primer
(Fermentas International INC, Ontario, Canada) by incubating
the reaction mixture at 37uC for 60 minutes, 72uC for 5 minutes
and the resulting first-strand cDNA was used as template in the
semiquantitative polymerase chain reaction (PCR). The cDNA
product was subjected to PCR (Vapo protect, eppendorf) for 25
cycles by LRP and MRP-1 specific primers (Table 1). The primers
used to amplify cDNA by PCR were designed using Primer
Express software. b-actin serve as an internal control. The PCR
products were electrophoresed on ethidium bromide stained 2%
agarose gel [7]. All samples were analyzed in triplicates. To
investigate expression of LRP and MRP-1 proteins, cells were
lysed in lysis buffer (1 M Tris, pH 7.5, 150 mM NaCl, 1%
Nonidet P-40, 10% glycerol, 100 mM EDTA, protease inhibitor
cocktail). Aliquots of each sample containing 100 mg proteins were
resolved in SDS-polyacrylamide gel, and transferred to poly-
vinylidene difluoride (PVDF) membranes. Membranes were then
probed with primary antibodies diluted at 1:1000 v/v for MRP-1
and LRP. The membranes were reprobed with anti-b-actin
antibody as loading control after being stripped with stripping
buffer. The membrane were washed three times with PBS
containing 1% Tween-20 and probed with secondary antibody.
Proteins were visualized by using enhanced chemiluminescence
detection reagents (Amersham Biosciences, Arlington Heights, IL)
Targeted Dual Drug Loaded NPs Reversing MDR
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[28]. Experiment was repeated at least thrice.
MDR gene expression following curcumin treatment by
real time RT-PCR
In brief, Y79 cells (50610
5 cell density) were treated with 2–
12 mg/ml concentrations of native curcumin for 2 days. Following
various treatments, total endogenous mRNA was isolated using
the RNeasy Mini kit (Qiagen, Hamburg, Germany). RNA was
treated with DNAse (Qiagen, Hamburg, Germany) to eliminate
any DNA contamination. Total RNA (l mg) was reverse-
transcribed to cDNA and the resulting first-strand cDNA was
used as template in the real-time PCR. The primers used to
amplify cDNA by real-time PCR were designed using Primer
Express software (Table 1). Real-time monitoring of PCR
amplification of cDNAs was done using qPCR Master Plus for
SYBR Green I-DTTP (Eurogentec, Belgium) with gene specific
primers, in real time PCR (DNA Engine Opticon2, MJ Research
Incorporated, BioRad, Philadelphia, USA). All samples were done
in triplicates. Relative quantification of gene expression was
performed using b-actin as an internal control [10].
Investigation of MDR protein expression following
curcumin treatment
To explore the effect of curcumin on the expression of LRP and
MRP-1, Y79 cells (10610
5 cell density) were treated with 2–
12 mg/ml concentrations of native curcumin for 2 days. Following
various treatments, protein was extracted and 100 mg proteins
were subjected to western blot analysis with MRP-1 and LRP
specific primary antibody. Experiment was performed in triplicates
[7]. Further, the effect of curcumin loaded nanoformulation (Cur-
NPs, Fol-Cur-NPs) on the expression of LRP and MRP 1 proteins
in comparison to native curcumin was investigated following
treatment of cells with 2 mg/ml curcumin in native form or
nanoformulation for 2 days.
Cellular uptake study by flow cytometry
Cellular uptake efficiency was studied using native curcumin,
curcumin loaded NPs and folate conjugated curcumin loaded NPs
(Fol-Cur-NPs) [28,31]. As curcumin has its intrinsic fluorescence
property it serve as a fluorescence probe to efficiently investigate
the uptake of drug loaded NPs. Briefly, 6 well plates (Corning, NY,
USA) were seeded with Y79 cells (folate receptor +ve) and A549
cells (folate receptor 2ve) at 100,000 cells per well density and
incubated with 1 ml of freshly prepared medium containing native
curcumin, Cur-NPs, Fol-Cur-NPs (equivalent to 10 mg/ml con-
centrations of native curcumin) for 2 hrs at 37uCi nC O 2
incubator (Hera Cell, Thermo Scientific,Waltham, MA). Cells
treated with only medium were used as respective controls. At the
end of the incubation period, the cells were collected and washed
three times with cold DPBS to eliminate excess of native curcumin
or NPs, which were not taken up by the cells. In all FACS analysis
(FACScan flow cytometer, Becton Dickinson), cell debris and free
particles were excluded by setting a gate on the plot of side-
scattered light (SSC) vs forward-scattered light (FSC). A total of
10,000 ungated cells were analyzed. The increase of fluorescence
intensity in the cells treated with native curcumin, and curcumin
loaded NPs relative to that of untreated control cells was expressed
as mean fluorescence increase relative to control. To verify that
the uptake is mediated via folate receptor, a competitive
experiment in presence of varying concentration of free folate
was performed. For the above study Y79 cells were treated with
(0–30 mM) of folate for 1 hr prior to incubation with Cur-NPs,
Fol-Cur-NPs or native curcumin and then subjected to above
protocol.
Qualitative cellular uptake analysis by confocal laser
scanning microscopy
Y79 and A549 cells were seeded in three sets in BioptechH tissue
culture plates (Bioptechs Inc. Butler, PA) at a density of 1610
5
cells/ml and incubated overnight at 37uC. Cells were treated with
either 10 mg/ml of native curcumin or Cur-NPs and Fol-Cur-NPs
(containing equivalent concentration of curcumin) in growth
medium for 2 hrs. At the end of the incubation period, the cells
were rinsed with DPBS three times and fixed with 70% ethanol for
20 min at 37uC. Subsequently cells were rinsed with DPBS and
1 mg/ml PI solution was added to stain cell nucleus for 30 min. PI
was washed three times using DPBS and cells were visualized by
confocal laser scanning microscope (Leica TCS SP5, Leica
Microsystems GmbH, Germany) equipped with an argon laser
using FITC filter (Ex(l) 488 nm, Em(l) 525 nm) and PI filter
(Ex(l) 530 nm, Em(l) 615 nm) [28]. Curcumin and PI showed
green colour and red colour respectively.
In vitro cellular cytotoxicity assay
The effect of native drugs and drug loaded nanoformulations on
cell proliferation was determined by MTT based colorimetric
assay [32]. Briefly, folate receptor expressing Y79 cell line and
folate receptor non-expressing cell line A549 were seeded in 96-
well plates (Corning, NY, USA) at density 4000 cells per well.
After the overnight incubation at 37uC, cells were treated with
varying concentrations of drugs (either as single native drug or
encapsulated in NPs or dual drugs in solution or encapsulated in
NPs). Cell viability was determined on 5
th day, following drug
treatment using MTT assay. A 10 ml/well MTT solution (5 mg/
ml) was added, plates were incubated at 37uC for 3 hrs, and then
the media was replaced with 100 ml of DMSO to dissolve the
formazan crystals. The absorbance was measured at 540 nm using
a microplate reader (Synergy HT, BioTekH Instruments Inc.
Winooski, VT, USA). The effect of each treatment was calculated
Table 1. Primers used in PCR analysis.
Forward primer Reverse primer Product size (bp)
MRP-1 ATGTCACGTGGAATACCAGC GAAGACTGAACTCCCTTCCT 155
LRP TGGCTTTGAGACCTCGGAAG CCAGTCTCTGAGCCTCATGC 230
b-actin CTGGCACCACACCTTCTACAAT AATGTCACGCACGATTTCCCGC 380
bcl2 GGATTGTGGCCTTCTTTGAG CCAAACTGAGCAGAGTCTTC 238
NFkB TCGTTTCCGTTATGTATGT CCTTGGGTCCAGCAGTTA 227
doi:10.1371/journal.pone.0032920.t001
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controls. The IC50 was determined by nonlinear regression
analysis using the equation for a sigmoid plot [33].
Cell cycle analysis by flow cytometry
Cell cycle is an important phenomenon that plays a crucial role
in developmental pathways, and is frequently deregulated in many
cancer diseases. The distribution of DNA in cell cycle was studied
by flow cytometry [28]. In brief, 1610
5 cells/ml were seeded in
25 cm
2 culture flasks (Corning, NY, USA) containing 5 ml media
and incubated overnight at 37uC. Next days, 5 ml of media each
containing 1.5 mg/ml concentrations of nutlin-3a (in solution or
nanoformulations) or 2 mg/ml of curcumin (in solution or
nanoformulations) or dual drugs (1.5 mg/ml nutlin-3a+2 mg/ml
curcumin) in solution or nanoformulations were added to the flasks
and the cells were incubated for 24 hrs in CO2 incubator at 37uC.
Cells treated with only medium was used as control. After
incubation time period, the cells were collected by centrifugation
at 91 g (SIGMA 3K30, Munich, Germany) and washed twice with
DPBS. The collected cells were resuspended in 500 mlo f
hypotonic propidium iodide solution which consists of 1 mlo f
propidium iodide (1 mg/ml), 1 ml of RNase A (10 mg/ml, MP
Biomedicals, Inc. Germany), and 0.5% Tween 20 in 500 ml of PBS
(0.01 M, pH 7.4) and incubated for 20 min at room temperature
in dark before analysis. Cell cycle distribution of the cells was
determined by analyzing 10,000 ungated cells using a FACScan
flow cytometer and Cell Quest software (FACS Calibur; Becton-
Dickinson, San Jose, CA). All experiments were performed in
triplicates.
Measurement of loss of mitochondrial membrane
potential (MMP)
Detection of the mitochondrial permeability transition event
provides an early indication of the initiation of cellular apoptosis.
Changes in the mitochondrial membrane potential were measured
by flow cytometry using JC-1 dye (cationic dye, which exhibits
potential-dependent accumulation in mitochondria) [28]. Briefly,
1610
5 cells/ml were seeded in 25 cm
2 culture flasks (Corning,
NY, USA) containing 5 ml media and incubated overnight at
37uC. After overnight incubation, cells were treated with 5 ml of
media each containing 1.5 mg/ml concentrations of nutlin-3a (in
solution or nanoformulations) or 2 mg/ml of curcumin (in solution
or nanoformulations) or dual drugs (1.5 mg/ml nutlin-3a+2 mg/ml
curcumin) in solution or nanoformulations and then incubated for
2 days in CO2 incubator at 37uC. Cells treated with only medium
was used as control. After completion of incubation period, cells
were collected by centrifugation at 91 g (SIGMA 3K30, Munich,
Germany) and washed twice with DPBS. The collected cells were
then treated with JC-1 staining solution (1 mg/ml JC-1 in DPBS
warm to 37uC) and incubated at 37uC for 20 min in a CO2
incubator. After incubation period, cells were washed twice with
DPBS. 10,000 cells were examined for each sample on a FL-1 (530
nm) versus FL-2 (585 nm) dot plot on a Becton Dickinson FACSort.
Experiment was performed in triplicates.
In vitro apoptosis studies
Apoptosis is a novel form of cell death, which plays a major role
during development, normal tissue homeostasis, and is deregulated
in many diseases including cancer. Induction of apoptosis in Y79
cells following drug treatment was studied by flow cytometry [28].
In brief, 5610
5 cells were allowed to grow in 25 cm
2 culture flasks
(Corning, NY, USA) containing 5 ml media for overnight at 37uC.
Subsequently, 5 ml of media each containing 1.5 mg/ml concen-
trations of nutlin-3a (in solution or nanoformulations) or 2 mg/ml
of curcumin (in solution or nanoformulations) or dual drugs
(1.5 mg/ml nutlin-3a+2 mg/ml curcumin) in solution or nanofor-
mulations were added to the flasks and the cells were incubated for
2 days in CO2 incubator at 37uC. Untreated cells were used as
respective control. At predetermined time period, the cells were
collected by centrifugation at 91 g (SIGMA 3K30, Munich,
Germany) and washed twice with DPBS. The pelleted cells were
resuspended in 500 ml of 1X binding buffer, 5 ml Annexin V-FITC
(1 mg/ml) and 1 ml propidium iodide (1 mg/ml) and incubated in
dark for 10 min. The apoptotic cells were determined by analyzing
10,000 gated cells using a FACScan flow cytometer and Cell
Quest software. All experiments were performed in triplicates.
Analysis of apoptotic signal proteins by western blotting
For western blot analysis, 3610
6 number of Y79 cells were
treated with 1.5 mg/ml concentrations of nutlin-3a (in solution or
nanoformulations) or 2 mg/ml of curcumin (in solution or
nanoformulations) or dual drugs (1.5 mg/ml-nutlin-3a and 2 mg/
ml-curcumin) in solution or nanoformulations for 2 days.
Following various treatments, cells were lysed with lysis buffer
and 100 mg of extracted proteins was subjected to western blotting
with specific primary antibody [26]. Experiment was repeated at
least thrice.
Real time quantitative PCR analysis
To explore the effect of drug combination over single drugs in
suppressing antiapoptotic signaling pathways, a quantitative
expression study of NFkB and bcl2 at gene level was investigated
by real time quantitative PCR analysis [10]. Briefly, 3610
6
number of Y79 cells were incubated with 1.5 mg/ml concentra-
tions of nutlin-3a (in solution or nanoformulations) or 2 mg/ml of
curcumin (in solution or nanoformulations) or dual drugs (1.5 mg/
ml nutlin-3a and 2 mg/ml curcumin) in solution or nanoformula-
tions for 2 days. Total mRNA was isolated and real-time PCR
amplification of cDNAs was done using above protocol. Relative
quantification of gene expression was performed using b-actin as
an internal control.
Statistical analysis
All experiments were repeated at least three times. Statistical
analyses were performed using a Student’s t test. Values of p,0.05
(*) were indicative of significant differences and very significant
difference if p,0.005 (**).
Results
Physiochemical characterization of drug loaded PLGA
nanoparticles
In an attempt to formulate site specific drug delivery system,
drug loaded PLGA nanoparticles were synthesized by single
emulsion method for targeting folate receptor over expressing
retinoblastoma cells. The two-step EDC/NHS activation method
enables the conjugation of amino groups of aminated folate to the
carboxyl groups of PLGA through an amide bond formation
[25,34]. Conjugation of folate to PLGA NPs was confirmed by
FTIR analysis and the amide bond peak at 1630.11 cm
21 in folate
functionalized NPs clearly indicates the formation of amide bond
following conjugation (Results S1, Figure S1) The conjugation
yield was found to be 8.5 mg and it was estimated that
approximately 8 mg of folate was conjugated per mg of
nanoparticles. An efficient nanoparticulate system should have a
high loading capacity to minimize the quantity of carrier required
for administration. In the present study we have achieved an
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PLGA NPs, when used singly or in combination (Table 2). Folate
conjugated NPs showed an entrapment efficiency of drug
comparable to that of unconjugated NPs. Similar result was
evident from experimental work of Misra et al. in doxorubicin
loaded NPs and NLS conjugated doxorubicin loaded NPs [30].
DLS analysis revealed that the formulated NPs had a unimodal
size distribution with a mean hydrodynamic diameter of
, 250 nm having polydispersity index , 0.1 and a negative zeta
potential of , 218 mV (Figure 1a, Table 2). Surface modification
of PLGA-NPs with folate had no significant effect on its physical
characteristics. A similar trend was also observed by Tseng et al.
when they conjugated biotinylated epidermal growth factor (EGF)
on gelatin nanoparticles [35]. TEM images (Figure 1b) showed
discrete spherical outline and monodispersed size (, 100 nm) of
PLGA NPs. The higher hydrodynamic diameter of NPs achieved
by DLS analysis as compared to the size obtained by TEM
analysis may be contributed by the hydration of the surface
associated PVA [30]. Sustained release of entrapped drug from
NPs is an important parameter for developing successful
formulations, as it enables constant amount of drug persistently
at site of action. As shown in Figure 2c and d, the release profile of
single drugs or drugs in combination from nanoparticulate system
exhibited a biphasic drug release pattern that was characterized by
a initial rapid release followed by a slower continuous release
phase over 15 days. The release of drugs from folate conjugated
NPs followed more or less similar release pattern to that of
unconjugated NPs (data not shown).
Expression of LRP and MRP-1 at m RNA and protein level
in Y79 cells
LRP and MRP-1 are the major MDR proteins conferring drug
resistance in retinoblastoma [6,7]. Presently, we have assessed the
expression of MRP-1 and LRP at mRNA and protein level in Y79
cells by semiquantitative PCR and western blotting technique
respectively. In the current study, we have found that the model
retinoblastoma cell line Y79 expresses significant level of LRP and
MRP-1 mRNA and protein as evident from Figure 2a and b.
Investigation of LRP and MRP-1 mRNA and protein
expression following curcumin treatments
Intense investigations have been performed by several research
groups, proving the potential of curcumin as MDR modulator
[11–13,30], but very few have been reported depicting the role of
curcumin in down regulating MDR gene expression. Here, we
have treated Y79 cells with increasing concentration of native
curcumin (2–12 mg/ml) for 2 days and examine the mRNA
expression by quantitative RT-PCR. The result clearly indicates a
concentration dependent down regulation in expression of MRP-1
and LRP mRNA following curcumin treatment (Figure 3a and b).
It is noteworthy that, cells treated with lowest concentration of
curcumin (2 mg/ml) revealed fifty fold decreases in expression level
of LRP mRNA. A similar trend was also observed for MRP-1
mRNA expression. The above results evidently indicates that,
curcumin plays significant role in regulating MDR at transcrip-
tional level; so, we have further assessed its effect at protein level
by western blotting. Interestingly, reduced expression of LRP and
MRP-1 protein was found, following treatment with increase
concentration of native curcumin (Figure 3c). The results clearly
showed a significant decrease in expression of LRP and MRP-1
proteins in cells treated with 2 mg/ml curcumin. As, the result
indicates a significant inhibition in expression of LRP and MRP-1
at gene and protein level with 2 mg/ml of native curcumin
treatment, we further investigated the effect of nanoformulation in
modulating the expression of these MDR proteins in comparison
to native curcumin at this particular concentration (Results S1,
Figure S2). The result evidently indicate that, folate targeted
curcumin loaded NPs is able to inhibit the expression of LRP and
mRP-1 proteins in an enhanced way compared to unconjugated
counterpart and native curcumin, pointing towards the therapeu-
tic potential of targeted NPs in overcoming multidrug resistance
(Figure S2).
Assessment of cellular uptake of different curcumin
loaded nanoformulations
Using the intrinsic fluorescence property of curcumin, a
comparative analysis of cellular uptake behavior of Fol-Cur-NPs,
Cur-NPs and native curcumin were performed in folate receptor
expressing Y79 cells and folate receptor non-expressing A549 cells
by flow cytometer and confocal laser scanning microscope. The
relative extent of cellular uptake of native curcumin, Cur-NPs and
Fol-Cur-NPs was presented in Figure 4a in terms of mean
fluorescence intensity (MFI) exhibited by the cells. As evident from
the figure, cellular uptake of Fol-Cur-NPs was nearly 3.3 times
greater than unconjugated NPs and 9 times more than native
curcumin in case of Y79 cell line. It is worth mentioning that,
there was no substantial uptake of Fol-Cur-NPs in comparison to
Table 2. Physico-chemical characterization of nanoparticle formulation.
Formulation Size (nm)
a Zeta Potential (mV)
b Polydispersity Index Entrapment efficiency (%)
c
Nut-NP 22667.3 218.460.57 0.1460.008 6564.3
Fol-Nut-NPs 23466.5 216.860.8 0.1160.005 6361.4
Cur-NP 22765.3 217.960.37 0.1860.007 8665.8
Fol-Cur-NPs 23665.5 216.260.49 0.1260.009 7762.1
Nut-Cur-NP 22966.3 218.960.87 0.1460.005 6463.2 (nutlin), 8563.3
(curcumin)
Fol-Nut-Cur-NPs 23564.6 215.960.59 0.1660.008 6361.2 (nutlin) 8462.4
(curcumin)
aSize in nm was measured by Zetasizer.
bZeta potential in mV was measured by Zetasizer.
cPolydispersity Index was measured by Zetasizer.
Entrapment efficiency of different drugs were measured by HPLC.
Size was measured by DLS using a Zetasizer. The surface charge was also measured by Zetasizer.
doi:10.1371/journal.pone.0032920.t002
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indicate that, the superior uptake of Fol-Cur-NPs in comparison to
native curcumin as well as Cur-NPs in Y79 cells is due to folate
receptor mediated endocytosis. To verify that the uptake of Fol-
Cur-NPs is mediated via folate receptor a competition of receptor
mediated uptake experiment using different amounts of free folate
in medium together with the Fol-Cur-NPs was performed. The
specificity of folate receptor mediated internalization of folate
conjugated NPs was evident from the decreased MFI value with
increasing concentration of free folate (Figure 4b). The inhibition
in uptake of Fol-Cur-NPs by free folate in a dose dependent
manner demonstrates that the particle uptake is mediated via
folate receptor in Y79 cell line. Figure 5, represents the qualitative
uptake study of Fol-Cur-NPs, Cur-NPs and native curcumin in
Y79 and A549 cell lines by confocal microscopy. Our result
demonstrated that, nanoformulation showed augmented fluores-
cence activity, the activity being maximum with Fol-Cur-NPs in
Y79 cell line at 2 hrs of incubation period. It is noteworthy to
mention here that, A549 cells treated with Fol-Cur-NP and Cur-
NPs showed similar fluorescence activity, while above nanofor-
mulations exhibited augmented fluorescence activity compared to
native curcumin. This visualization result was consistent with those
presented in the flow cytometry analysis.
Enhanced cytotoxicity of folate functionalized dual drug
loaded NPs
Enhanced therapeutic potentiality of drug loaded polymeric
NPs is the outcome of their cellular uptake and intracellular
distribution [32]. In the present study, the chemosensitivity of the
nanoformulation (unconjugated and conjugated NPs) as compared
to native drugs was investigated at dose dependent manner for
5 days in folate receptor expressing Y79 cells and folate receptor
negative A549 cells. It can be perceived from MTT assay that, Fol-
Nut-NPs and Fol-Cur-NPs exhibited significantly higher cytotox-
icity compared to native drugs or unconjugated drug loaded NPs
at all drug concentration in Y79 cells (Figure 6a, b). The IC50 of
Fol-Nut-NPs in Y79 cells was found to be 6 and 2.4 times lowered
compared to native drug and unconjugated NPs respectively
Figure 1. Physiochemical characterization of nanoformulations. Size of NPs (a) was measured by DLS. (b) TEM analysis of drug loaded NPs
depicting the spherical nature of the nanoformulation. Scale bar is 100 nm. (c and d) Sustain release phenomenon exhibited by drug loaded
nanoformulations. The values are shown as mean6SD, n=3.
doi:10.1371/journal.pone.0032920.g001
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the IC50 value to 4.1, 3.2 times as compared to free curcumin and
Cur-NPs respectively (Table 3). It is noteworthy that, cells treated
with drugs in combination (nutlin-3a and curcumin either in
solution or unconjugated/folate conjugated nanoformulations)
showed augmented cytotoxicity, compared to single drug treat-
ments (Figure 6c). The IC50 of Fol-Nut-Cur-NPs was found to be
35 and 8.6 times lower than native drugs in combination and
uncojugated dual drug loaded NPs (Table 3). This clearly indicates
that Fol-Nut-Cur-NPs elicited enhanced anti-proliferative activity
as compared to dual drugs in solution or encapsulated in
unconjugated NPs. To test the hypothesis that, enhanced
cytotoxicity of folate conjugated NPs over unconjugated NPs is
due to higher uptake of the conjugated system; we have studied its
efficacy in a folate receptor negative cell line A549 and found that
there is no significant difference in IC50 of Fol-NPs compared to its
unconjugated counterpart (Figure 6d, e, f, Table 3). This clearly
indicates that, the augmented cytotoxicity associated with folate
conjugated NPs may be attributed to folate receptor mediated
enhanced endocytosis.
Cell cycle analysis
Both the chemotherapeutic agents (nutlin-3a and curcumin) are
potent inducer of cell cycle arrest in G1 and/or G2 phase of cell
cycle [28,29,36]. To determine whether co-administration of
Figure 2. Expression study of MDR mRNA and proteins.
Expression of LRP and MRP-1 mRNA (a) and proteins (b) was
determined by semiquantitative PCR and western blotting respectively.
RNA was extracted and PCR was performed with gene specific primers.
The PCR products were run in 2% agarose gel. b-actin serves as control
for equal loading. The expression of MDR proteins was further
confirmed by western blot analysis (b). Cells were lysed and expression
of MDR proteins was analysed by respective primary antibodies. A549
cells act as positive control for LRP and MRP-1 expression, while HEK
and SIHA serve as negative control for MRP-1 and LRP expression
respectively. The results are representative of three independent
experiments.
doi:10.1371/journal.pone.0032920.g002
Figure 3. qRT PCR analysis of the effect of curcumin treatment on MRP-1 and LRP gene/protein expression. Y79 cells were treated
with increasing concentration of native curcumin for 48 hrs and relative expression of MRP-1 and LRP mRNA was measured (a and b). b-actin serves
as internal control. Dose dependent inhibition of MDR mRNA was evident with curcumin treatment (a and b). Dose dependent inhibition of MRP-1
and LRP protein expression following curcumin treatment was also confirmed by western blotting (c).
doi:10.1371/journal.pone.0032920.g003
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arrest in Y79 cells, cell cycle analysis were performed following
drug treatments for 24 hrs. From the result it becomes evident
that, nutlin-3a (single formulations) cause G1 arrest while
curcumin (single formulations) exhibited G2 phase arrest in Y79
cells (Figure 7). Notably, folate conjugated drug loaded NPs either
Fol-Nut-NPs or Fol-Cur-NPs showed augmented activity than
unconjugated counterpart. Interestingly, dual treatment of cells
with both the drugs in solution or nanoformulations resulted in G2
phase arrest of cell cycle, the maximum arrest being exhibited by
Fol-Nut-Cur-NPs.
Drug-induced perturbation in mitochondrial
transmembrane potential
Loss of MMP can be detected by a fluorescent dye JC-1, which
forms J-aggregates or monomers, depending on the state of
mitochondrial membrane potential, with the emissions of the two
dye forms detectable by flow cytometry at 585 nm (FL2) or
530 nm (FL1), respectively [37]. The high mitochondrial mem-
brane potential of normal cells loaded with JC-1 allows for the
formation of J-aggregates, as the mitochondrial membrane
potential is loss, these aggregates dissipate into monomers.
Figure 8 shows the loss in MMP of Y79 cells incubated with
nutlin-3a or/and curcumin (in solution or nanoformulations), as
the population of cells shifts to a lower JC-1 aggregate state and a
concurrent higher JC-1 monomer state. As evident from the result,
cells incubated with 1.5 mg/ml of Fol-Nut-NPs show loss of MMP
in an enhanced way as compared to native drug or unconjugated
counterpart. Similarly, with 2 mg/ml of curcumin treatment, Y79
cells treated with Fol-Cur-NPs demonstrated augmented loss of
MMP as compared to same concentration of native curcumin and
unconjugated NPs. It is noteworthy to mention that, drug in
combination (as native form or nanoformulations) depicted an
augmented loss in MMP compared to single drug treatments and
Fol-Nut-Cur-NPs shows synergistic effect with enhanced thera-
peutic ability than native drug in combination or uncojugated
counterpart.
Supra-additive induction of apoptosis mediated by folate
decorated dual drug loaded NPs
In our studies, we found that cell cycle arrest and loss of MMP
ultimately result in apoptosis of the cells (Figure 9). The result
depicts the presence of a significant fraction of apoptotic cell
population following treatment with various drugs individually (in
solution or nanoformulation) or in combination (in solution or
nanoformulation). Cells treated with 1.5 mg/ml Fol-Nut-NPs
showed enhanced apoptotic activity compared to native drug. In
a similar experiment, cells treated with Fol-Cur-NPs (2 mg/ml)
elicited significant fraction of cell death following apoptosis than
unconjugated substitute and native curcumin. Combination
therapy act synergistically, as evident from the higher apoptotic
cell death following simultaneous treatment with both the drugs (in
solution or entrapped in NPs). It is worth mentioning that folate
conjugated dual drug loaded NPs was competent enough to induce
a more profound apoptotic cell death.
Investigation of apoptosis inducing pathways following
combination therapy
Resistance to apoptosis is a hallmark of cancer, with both the
loss of proapoptotic signals and the gain of anti-apoptotic
Figure 4. Uptake study by flow cytometry. Conjugation of folate on to nanoparticle increases its uptake in Y79 (a). A suspension of curcumin
and Cur-NPs, Fol-Cur-NPs (10 mg/ml) was incubated with folate receptor expressing Y79 and non-expressing A549 cells (100,000 cells) for 2 hrs, and
uptake of NPs by the cells were determined with flowcytometer by measuring the mean fluorescence intensity value. Competitive inhibition of
uptake of Fol-Cur-NPs by addition of free folate (b). Y79 cells were treated with 0–30 mM of free folate for 1 h prior to incubation with curcumin and
Cur-NPs, Fol-Cur-NPs and then subjected to above protocol. Mean fluorescence intensity of curcumin fluorescence in the cells was measured (n=3;
mean6s.e.m, (*) p,0.05 drug in solution versus drug loaded NPs, (**) p,0.005 drug in solution versus Fol-Cur-NPs).
doi:10.1371/journal.pone.0032920.g004
Figure 5. Qualitative uptake analysis by confocal microscopy.
Cells were treated with native curcumin, Cur-NPs, Fol-Cur-NPs (10 mg/
ml) and incubated for 2 hrs. Fol-Cur-NPs showed augmented fluores-
cence activity compared to native drug and unconjugated NPs in Y79
cell line, while no significant difference in uptake of Fol-Cur-NPs
compared to Cur-NPs was evident in A549 cell line. Data represented as
mean6s.e.m., n=3.
doi:10.1371/journal.pone.0032920.g005
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chemotherapeutic agents exert their antitumor effect by triggering
apoptosis signal transduction pathways (intrinsic and/or extrinsic)
in cancer cells [38]. In the present study, we aim to define, which
apoptotic pathway get activated in Y79 cells following treatment
with drug in combination (in native form or nanoformulation) or
single formulations. The result indicates the involvement of
components of both the pathways to initiate apoptosis. Figure 10
shows down regulation of procaspases 8, 3 respectively and
cleavage of PARP, which indicates towards the activation of
extrinsic pathway. Significant down regulation of above proteins
was evident in cells exposed to Fol-Nut-NPs or Fol-Cur-NPs
compared to their unconjugated counter part and native drugs. It
is worth mentioning that, drug in combination show better result
and a more profound effect was exhibited by Fol-Nut-Cur-NPs.
Mitochondria play an essential role in apoptosis triggered by
various chemical agents [39]. Mitochondrial response during
apoptosis includes down regulation of bcl2, activation of BAX and
release of cytochrome c into the cytosol where it binds to Apaf-1,
allowing the recruitment of caspase-9 and formation of an
apoptosome complex, resulting in caspase-3 activation and
execution of cell death by PARP cleavage [40]. To determine
whether mitochontrial depolarization by nutlin-3a and/or curcu-
min leads to initiation of this cell death mechanism, we have
investigated the key proteins associated with mitochondrial
pathway of apoptosis by western blotting. Our result shows down
regulation of bcl2 and over expression of anti-apoptotic proteins
like tBid, BAX (that confer cytochrome c release by interacting
with mitochondrial membrane) and indicates towards the
involvement of mitochondrial pathway in apoptosis. The above
finding was further supported by the presence of cytochrome c
following drug treatments. Notably, down regulation of procas-
Figure 6. Cytotoxicity analyses. Dose dependent cytotoxicity study of curcumin or/and nutlin-3a in Y79 cells (a), (b), (c) and A549 cells (d), (e), (f).
Different concentration of nutlin-3a or/and curcumin either as solution or encapsulated in NPs (NPs, Fol-NPs) and void NPs were added to wells with
medium. The extent of growth inhibition was measured at 5
th day using MTT assay and inhibition was calculated with respect to untreated controls
cells. Data are expressed as mean6s.e.m., n=6, (*) p,0.05 drug in solution versus drug loaded NPs, (**) p,0.005 drug in solution versus Fol-NPs.
& Void NPs,N Native drug, m Drug loaded NPs, . Folate conjugated NPs.
doi:10.1371/journal.pone.0032920.g006
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also observed. It is noteworthy to mention that, enhanced
expression of antiapoptotic proteins, cytoplasmic cytochrome c
and significant reduction in expression of procaspases was evident
in cells treated with Fol-Nut-Cur-NPs.
Many independent apoptosis regulatory pathways also operate
in cells. One such pathway is the cell survival pathway regulated
by NFkB and IkBa proteins. In the present study, we for the first
time reporting that, both curcumin and nutlin-3a can effectively
inhibit NFkB activity in Y79 cells. An increased expression of
inactive NFkB was evident with Fol-Nut-Cur-NPs compared to
respective unconjugated counterpart (single or dual formulations)
(Figure 10). Interesting, expression of IkBa protein (associated
with NFkB pathway) was found to be enhanced in cells treated
with curcumin in solution or nanoformulation (Figure 10).
However, no significant difference in its expression level was
evident in cells exposed to nutlin-3a in single formulation. This
clearly indicates that, nutlin-3a plays no role in regulating the
other protein members associated with NFkB pathway. It is
noteworthy to mention that; drug in combination shows up-
regulation of IkBa in an enhanced manner, thus it point towards
the fact that, our dual drug loaded nanoformulation is capable of
activating multiple signaling pathways.
Induction of apoptosis by down-regulation of anti-apoptotic
gene bcl 2 and NFkB bcl-2 is the prominent member of a family of
proteins that are responsible for deregulation of apoptosis and
prevention of death in cancer cells [41,42]. bcl-2 overexpression
and/or activation has been correlated with resistance to
chemotherapy and radiotherapy [43]. Notably, overexpression of
bcl-2 protein in retinoblastoma, confer drug resistance and make
the disease more aggressive [3]. In the present study, we have
shown the enhanced down regulation of bcl-2 protein expression
in cells treated with drug in combination over their respective
single drug formulation (Figure 10). Notably, Fol-Nut-Cur-NPs
elicited more profound effect compared to unconjugated counter-
part and native drug in combination. To confirm the above
Table 3. Cytotoxic effect of drug loaded nanoformulations.
Treatments IC50 (mg/ml)











Figure 7. Effect of native drug and drug loaded NPs and folate conjugated NPs as single agents or in combination on cell cycle
distribution of Y79 cells. 1610
5 cells/ml were treated with native nutlin-3a, Nut-NPs, Fol-Nut-NPs (1.5 mg/ml), curcumin, Cur-NPs, Fol-Cur-NPs
(2 mg/ml) and Nutlin+Curcumin, Nut-Cur-NPs, Fol-Nut-Cur-NPs (1.5 nutlin+2 mg/ml curcumin). For cell cycle analysis, after 24 hrs 500 ml of hypotonic
propidium iodide solution was added to treated cells, incubated at room temperature in dark for 1 h before flow cytometric analysis. Content of DNA
is represented on the x-axis; number of cells counted is represented on the y-axis (n=3). The region marked M1, M2, M3 and M4 represent G1, S, G2
and G0 phase respectively, of the cell cycle.
doi:10.1371/journal.pone.0032920.g007
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5 cells/ml were treated with
native nutlin-3a, Nut-NPs, Fol-Nut-NPs (1.5 mg/ml), curcumin, Cur-NPs, Fol-Cur-NPs (2 mg/ml) and Nutlin+Curcumin, Nut-Cur-NPs, Fol-Nut-Cur-NPs (1.5
nutlin+2 curcumin mg/ml) for 48 hrs. Cells treated with only medium was used as controls. After completion of incubation period, cells were treated
with JC1 staining solution (1 mg/ml in warm DPBS) and incubated at 37uC for 20 min in a CO2 incubator. After incubation period, cells were examined
by flow cytometer. Data represented as mean6s.e.m., (n=3). Folate targeted dual drug loaded NPs showed higher loss of MMP in Y79 cells compared
native drugs (single or in combination) and unconjugated single or dual drug loaded NPs.
doi:10.1371/journal.pone.0032920.g008
Figure 9. Induction of apoptosis in Y79 cell line nutlin-3a or/and curcumin (in solution or nanoformulation. 1610
5 cells/ml were
incubated with native nutlin-3a, Nut-NPs, Fol-Nut-NPs (1.5 mg/ml), curcumin, Cur-NPs, Fol-Cur-NPs (2 mg/ml) and Nutlin+Curcumin, Nut-Cur-NPs, Fol-
Nut-Cur-NPs (1.5 nutlin+2 curcumin mg/ml) for 48 hrs and apoptosis percentage was measured using standard Annexin V-FITC method. Data
represented as mean6s.e.m., (n=3).
doi:10.1371/journal.pone.0032920.g009
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mRNA following different treatment by real time RT-PCR. Our
result indicates an enhanced down regulation of mRNA expression
in cells treated with Fol-Nut-Cur-NPs compared to unconjugated
counterpart substitute and native drug (Figure 11a). Like bcl-2, cell
survival protein NFkB plays an important role in signal
transduction pathway regulating cell survival and apoptosis. In
the present study, we are for the first time reporting that both
curcumin and nutlin-3a was found to be effective in inhibiting
NFkB transcriptional activity in Y79 cells. A decreased expression
of NFkB mRNA was evident with Fol-Cur-NPs and Fol-Nut-NPs
compared to respective unconjugated counterpart (Figure 11b).
Interestingly, drug in combination was potent enough in
inactivating NFkB than single drug treatments and Fol-Nut-Cur-
NPs exhibited 7.2 and 2.8 fold lower expression of mRNA
compared to unconjugated NPs or native drug in combination
respectively. Our result disclose the fact that, at transcription level
also, folate decorated dual drug loaded NPs was efficient to target
many key pathways involved in regulation of apoptosis.
Discussion
Drug resistance represents a major cause for therapeutic failure
and death in retinoblastoma treatment. An important cause
behind the execution of resistance by this overwhelming disease is
the enhanced cellular efflux of a wide variety of structurally
distinct classes of chemotherapeutic agents because of overexpres-
sion of the MDR proteins like MRP-1 and LRP etc. Addition to
that, overexpression of antiapoptotic protein bcl-2, NFkB and
inactivation of many signaling pathways like MDM2 mediated
inactivation of p53 proteins, mutation of pRb gene notably
contribute to drug resistance in retinoblastoma [3,4]. Considering
the relative importance of efflux transporters to execute drug
resistance in diverse cancer, many research activities have been
conducted till date to circumvent above lacunae by exploring the
role of curcumin in modulating MDR activity. In three
independent studies, Chearwae et al. have shown that, curcumin
could effectively inhibit the function and expression of the major
MDR proteins (P-gp, MRP-1, BCRP) in various drug resistance
cell line in vitro [11–13]. Recently, Thiyagarajan et al. for the first
time have investigated the role of curcumin in modulating LRP
expression in Y79 cell line and found that under in vitro system,
curcumin can efficiently down regulate LRP protein expression,
thereby enhances the cytotoxicity of anticancer drug etoposite [7].
Although, curcumin has shown its potency as MDR modulator in
vitro, however its clinical application is greatly limited by its poor
aqueous solubility, poor bioavailability and short plasma half life
etc. [17]. Thus, strategy to enhance the bioavailability and stability
Figure 10. Study of apoptosis regulatory proteins by western blot analysis. Y79 cells were incubated with native nutlin-3a, Nut-NPs, Fol-
Nut-NPs (1.5 mg/ml) or curcumin, Cur-NPs, Fol-Cur-NPs (2 mg/ml) or Nutlin+Curcumin, Nut-Cur-NPs, Fol-Nut-Cur-NPs (1.5 nutlin+2 curcumin mg/ml) for
48 hrs time period, and various apoptosis associated proteins were analyzed by western blotting. Lane 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 represents
control, native nutlin-3a, Nut-NPs, Fol-Nut-NPs, curcumin, Cur-NPs, Fol-Cur-NPs, Nutlin+Curcumin, Nut-Cur-NPs, Fol-Nut-Cur-NPs respectively.
Experiment was performed in triplicates.
doi:10.1371/journal.pone.0032920.g010
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modulator clinically. Recently, our group has tried to increase the
bioavailability of native curcumin to many folds by encapsulating
it in nanoparticulate system in an animal model [19]. Therefore,
we hypothesize that, by encapsulating curcumin in polymeric
nanoparticulate system, we can augment the MDR modulatory
activity of curcumin in vitro/in vivo and propose that such a
therapeutic strategy can open new horizon for the treatment of
cancer with drug resistance phenomena in clinical setup. A
strategy that has been investigated in recent year to enhance the
therapeutic potentiality of drug loaded carrier system is co-delivery
of two potential therapeutic agents which act either additively or
synergistically to kill tumor cells in an enhanced way. In the
present state of affairs, we take advantage of combination therapy
and aimed to develop a therapeutic nanocarrier capable of drug
delivery and molecular targeting for simultaneous reversion of
drug resistance by functional inhibition of MDR proteins and
hitting of multiple signaling targets associated with cell survival or
apoptosis. With this concept in mind, we developed a folate
targeted polymeric nanopartices co-loaded with anticancer drug
nutlin-3a (a potent activator of p53, also inactivate NFkB) and
chemo-sensitizer curcumin (effectively modulate MRP-1 and LRP
activity) to act additively or synergistically for enhanced thera-
peutic efficacy in multidrug resistance Y79 cells. We further,
highlighted the role of curcumin in modulating the functionality of
LRP and MRP1 in Y79 cell line.
For developing an efficient drug delivery vehicle, physicochem-
ical characterization of the drug loaded nanosystem is of prime
importance, as it significantly influences the in vitro and in vivo
performance of the entrapped drug. In the present work, we have
developed small sized NPs, which could show higher accumulation
at tumor sites due to their escape by the reticuloendothelial system
Figure 11. qRT PCR of bcl-2 and NFkB mRNA. Down regulation of bcl2 and NFkB gene expression by qRT PCR following treatment with native
nutlin-3a, Nut-NPs, Fol-Nut-NPs (1.5 mg/ml), curcumin, Cur-NPs, Fol-Cur-NPs (2 mg/ml) and Nutlin+Curcumin, Nut-Cur-NPs, Fol-Nut-Cur-NPs (1.5
nutlin+2 curcumin mg/ml) for 48 hrs.
doi:10.1371/journal.pone.0032920.g011
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would enhance the therapeutic efficiency of the anticancer drug
as well as could sustain its therapeutic effect. Our nanoparticulate
formulation solely exhibit a sustain release phenomena, under in
vitro condition as depicted in Figure 1c and d. Rapid initial
release is attributed to the drug which is adsorbed or weakly
bound to large surface area of the nanoparticles, and the slow
release could be caused by diffusion of the drug inside the
nanoparticles [45].
As our aim is to reverse MDR in retinoblastoma cell line Y79 to
enhance the therapeutic potentiality of nutlin-3a, we assessed the
effect of curcumin on expression of MRP-1 and LRP mRNA
(Figure 3a, b,). Our result demonstrated a dose dependent
inhibition of MRP-1 and LRP gene expression following curcumin
treatment. The MDR gene suppressing activity of curcumin was
further assessed at protein level by western blotting and the result
clearly indicates down regulation of MRP-1 and LRP protein with
increasing curcumin concentration (Figure 3c). The protein
expression study was in accordance with gene expression analysis
and point towards the fact that curcumin is a potent modulator of
MDR proteins. Similar type of work has been conducted by many
research groups where they have found that; curcumin is effective
enough to modulate function and expression of various MDR
proteins (Pgp, MRP-1, LRP etc.) in a dose or time dependent
manner [7,12,46]. Noteworthy, it has also been reported that
curcumin get metabolized at longer time points and the active
metabolite like tetrahydrocurcumin plays the key role in
modulation of MDR protein and gene expression [47]. To this
Figure 12. Schematic presentation of proposed signaling pathway activated by folate targeted dual drug loaded nanoparticles.
Folate conjugated NPs loaded with nutlin-3a (o) and curcumin (N) synergistically activates major apototic proteins or down regulates major
antiapoptotic proteins involved in apoptosis pathway.
doi:10.1371/journal.pone.0032920.g012
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regulating MDR exhibited by Y79 cell needs further investigation.
The enhanced chemotherapeutic activity of the ligand targeted
carrier system was assessed in terms of cellular uptake efficiency of
the carrier system. Our results clearly demonstrate that, uptake of
Fol-Cur-NPs was significantly greater than that of the unconju-
gated particle and native drug in folate receptor expressing Y79
cells (Figure 4a). Further, the specificity of folate receptor mediated
internalization of conjugated NPs was evident from the decreased
uptake of Fol-Cur-NPs with increasing concentration of free folate
(Figure 4b). The greater uptake of Fol-Cur-NPs in Y79 cells clearly
indicates the role of higher folate receptor expression and receptor
mediated binding and uptake of conjugated NPs. Intensive
investigation have been done on folate-receptor mediated uptake
of drugs and macromolecules in recent years. Elegant work
conducted by Wang et al. have demonstrated increased level of
uptake of folate conjugated paclitaxel loaded micelles compared to
unconjugated micelles in MCF7/ADR cells, thus proving that
targeted delivery of carrier system results in enhanced and
discriminatory drug uptake by the cancer cells [48]. Besides this,
the enhanced uptake level of folate conjugated NPs may be due to
the reduced exocytosis of conjugated system than unconjugated
NPs [49]. Enhanced intracellular uptake of Fol-Cur-NPs by Y79
cells was substantially confirmed by confocal microscopy, where
augmented fluorescence activity of cells exposed to Fol-Cur-NPs
indicates that conjugated system were internalized more in
comparison to native drug and unconjugated Cur-NPs (Figure 5).
Simultaneous delivery of anticancer drug and chemosensitizer
ultimately aims towards the better efficacy of drug in terms of
cellular cytotoxicity. By encapsulating anticancer drug nutlin-3a
and chemosensitizer like curcumin with inherent cytotoxic activity,
we hypothesized to achieve enhanced antiproliferative activity in
drug resistance Y79 cells. Our result demonstrated a sharp
discrimination in cell inhibition with dual drug loaded nanofor-
mulations or native drug in combination compared to respective
single drug counter parts, thus stressing the role of curcumin in
combination in inhibiting MDR activity (Figure 6a, b, c). Similar
type of result was obtained by Patil et al. when they used the
cytotoxic drug paclitaxel and chemosensitizer tariquidar [21].
Further, the enhanced cytotoxicity exhibited by folate targeted
dual drug loaded NPs as compared to unconjugated dual drug
loaded NPs or native drug in combination could be attributed to
enhanced accumulation of folate decorated drug loaded NPs. The
above hypothesis was supported by the uptake result in which
enhanced accumulation of Fol-Cur-NPs compared to Cur-NPs
was evident in folate receptor expressing Y79 cells, while no
remarkable difference in cellular accumulation of Fol-Cur-NPs
and Cur-NPs was found in folate receptor non-expressing A549
cells (Figure 4 and 5). The concept of receptor mediated enhanced
accumulation leading to higher cytotoxicity was further confirmed
by MTT assay of folate targeted dual drug loaded NPs and
unconjugated or native counterpart in folate receptor nonexpres-
sing A549 cell line (Figure 6d, e, f). Nutlin-3a and curcumin
inhibits cell growth and proliferation primarily through cell cycle
arrest and apoptosis inducing mechanism [36,50]. In our studies,
treatment of Y79 cells with Fol-Nut-NPs and Nut-NPs resulted in
greater proportion of cell in G1 phase as compared to cells treated
with drug in solution (Figure 7). Similarly, cells incubated with Fol-
Cur-NPs, Cur-NPs showed higher proportion of cell in G2 phase
compared curcumin in solution. Studies conducted by Park et al.
suggested that NPs are more effective in controlling cell cycle
analysis than native drug in A549 and HeLa cells [51]. However,
greater efficiency of folate conjugated drug loaded NPs in arresting
more number of cells can be explained on the basis of increased
intracellular drug level at the site of action for a longer period of
time than native drug and unconjugated NPs [49,52]. Interest-
ingly, drug in combination showed G2 phase arrest (Figure 7).
This issue can be further addressed by highlighting the role of p53
in cell cycle regulation. It is a well-known fact that p53-dependent
cell cycle arrest at G1 phase is in part a consequence of up-
regulation of p21 protein. p21 inhibits G1 cyclin dependent kinase,
leading to a G0-G1 arrest of the cell cycle [53]. Further, p53 has
been shown to induce G2 arrest by primarily perturbing the
function of cyclin B1/cdc2 complex [54]. Additionally, activation
of p53 protein also leads to expression of protein like 14-3-3s
involved in G2 phase arrest, thus ultimately results in arrest of cells
at G2 phase [55]. As nutlin-3a is a potent activator of p53 protein
it is anticipated that, enhanced accumulation of nutlin-3a and
curcumin due to MDR reversing activity of curcumin may leads to
enhanced cell arrest at G2 phase of cell cycle. Recent findings have
suggested that alterations of mitochondrial function may be
important for early indication of apoptosis [56]. In the present
study, the augmented loss of MMP in Y79 cells following Fol-Nut-
Cur-NPs treatment compared to unconjugated counterpart (drug
in single or combination) or drug in solution (single or
combination) can be attributed to increased drug accumulation
due to receptor mediated endocytosis and reduced efflux because
of MDR modulatory effect of curcumin (Figure 8). The molecular
mechanism of nutlin-3a or curcumin mediated loss of MMP could
be well explored by highlighting the role of cytochrome c (Cyt-c).
Cyt-c is normally localized in the space between the outer and
inner mitochondrial membrane and is only released into the
cytosol in the setting of apoptosis [57]. The expression of
cytoplasmic Cyt-c in Y79 cells as evident from our western result
(Figure 10) supports the point that nutlin-3a or/and curcumin
mediated release of Cyt-c which results in loss of MMP. From
Figure 10, it can also be said that at molecular level greater
accumulation of folate targeted dual drug loaded nanoformulation
with MDR modulating activity results in higher expression of Cyt-
c, resulting in enhanced loss of MMP.
Apoptosis is a key regulator of physiological growth control and
regulation of tissue homeostasis but it is highly deregulated in
cancer. Execution of apoptosis is regulated by plethora of cell
signaling pathways and current chemotherapeutic agents solely
exhibit their action by targeting these signaling pathways. Our
results demonstrated higher fraction of apoptotic cell death in Y79
cells treated with Fol-Nut-NPs or Fol-Cur-NPs than unconjugated
counterpart or native drug in solution following site specific
sustained release pattern (Figure 9). It is noteworthy mentioning
that, drugs in combination (either in solution or nanoformulation)
elicited enhanced apoptotic activity compared to single drug
treatment, the activity being maximum with Fol-Nut-Cur-NPs.
The enhanced therapeutic ability of dual drug formulation over
single drug can be addressed by the fact that, two or more drug in
combination with distinct cellular targets are able to hit multiple
signaling cascades simultaneously, thus ultimately causing en-
hanced apoptosis. In the present work, we anticipate that, our dual
drug loaded nanoparticulate system also target multiple signaling
pathways simultaneously and able to cause enhance apoptosis
(Figure 12). The concept that, drug in combination hits multiple
cellular targets and cause increased cell death was further
confirmed by exploring the expression of various apoptotic or
anti-apoptotic proteins by western blot analysis. In general two
apoptotic signaling pathways (extrinsic and intrinsic) operates in
cell to regulate the apoptosis mechanism [38]. The extrinsic
mechanism of apoptosis involves activation of caspases like caspase
7, 8, 3 and finally cleavage of PARP. In a similar way intrinsic
mechanism of apoptosis is triggered by activation of BAX, PUMA,
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9, caspase 3 and PARP cleavage [38]. An interconnected
mechanism of apoptosis that initiated as external pathway but
end as internal mitochondrial pathways was mediated by cleavage
of bid [38]. All these signaling pathways either act alone or merge
to elicit apoptotic response. To investigate by which pathways our
dual drug loaded NPs exhibit its apoptotic response, we performed
western blot analysis. In the present work we found the expression
of BAX and cytochrome c, down regulation in expression of
procaspases 9, procaspase 7, procaspase 3 and expression of
cleaved PARP in cells treated with all formulation either used as
single agent or in combination. In addition to that expression of t-
bid (the connector between extrinsic and intrinsic pathways)
clearly indicates the combination effort of both the pathways in
eliciting apoptotic response (Figure 10). Notably, folate functiona-
lized nanosytems showed greater efficacy following site specific
drug delivery, however enhanced activity of drug in combination
in triggering apoptosis response could be attributed to the
synergistic action of both the drugs.
In addition to LRP and MRP-1 in eliciting drug resistance in
retinoblastoma, antiapoptotic protein bcl2 and cell survival protein
NFkB also play significant role in multidrug resistance of
retinoblastoma. Our result demonstrates significant down regula-
tion of both the proteins following treatment with native drugs or
nanoformulation (used as single agent or in combination
(Figure 10). Notably, folate targeted dual drug loaded nanofor-
mulation exhibited maximum inhibition due to enhanced uptake
by receptor mediated endocytosis and reduced efflux of drug by
modulation of MRP proteins. At the transcriptional level also
expression of both the gene was down regulated by all the
formulation, the suppression being maximum with Fol-Nut-Cur-
NPs (Figure 11).
An ultimate goal in cancer therapy is to devise individually
tailored treatment strategy that targets growth-promoting path-
ways and circumvents drug resistance. With this aim, in the
present study we formulated dual drug loaded nanocarrier with
property of reversing drug resistance and ability to targets many
growth-promoting pathways. Further, for site specific delivery of
therapeutic payload we functionalized the carrier with folate
ligand. Our results clearly indicate that, nutlin-3a along with
curcumin in PLGA nanoparticles resulted in significantly en-
hanced cellular accumulation of drugs, and greater cytotoxicity in
MDR over expressing cells. Co-delivery of both therapeutic agents
synergistically acts to induce better cell cycle arrest, loss of MMP
and enhanced apoptosis by triggering many signaling pathways.
Overall, we anticipate that this drug combination will show new
horizon in treatment of cancer that exhibits multidrug resistance
phenomenon.
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